Side-by-side · Research reference

CardiogenvsGDF-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-StrongHUMAN-REVIEWED23/48 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

01Mechanism of Action

Parameter

Cardiogen

GDF-8

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

GDF-8

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

—

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

—

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

—

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

—

Clinical use

—

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

Inhibition strategies

—

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

VLP immunogen (MS2.87-97)

—

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

Dual immunization (MSTN + Activin A)

—

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

Gene editing outcomes

—

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

03Metabolic / Fat Loss Evidence

Parameter

Cardiogen

GDF-8

Primary mechanism

—

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

Human genetic evidence

—

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

Animal model outcomes

—

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

Adipose-muscle crosstalk

—

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

Metabolic benefits

—

Improved metabolic health in genetic MSTN null modelsJacquez 2026

Age-related effects

—

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

04Side Effects & Safety

Parameter

Cardiogen

GDF-8

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Genetic null phenotype

—

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

Antibody cross-reactivity risk

—

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

VLP immunotherapy safety

—

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

Echocardiography

—

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

Pleiotropic effects (gene editing)

—

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

Assay variability

—

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

05Administration Protocol

Parameter

Cardiogen

GDF-8

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

3. Timing

Variable — often evening injection. No established circadian preference.

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

—

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

GDF-8

— no documented stacks